IAIM
LSTA icon

International Assets Investment Management’s Lisata Therapeutics LSTA Stock Holding History

International Assets Investment Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8K Hold
5,000
– – ﹤0.01% 1673
2026
Q1 		$25.1K Hold
5,000
– – ﹤0.01% 1434
2025
Q4 		$9.3K Buy
+5,000
New +$11.1K ﹤0.01% 1680

Other funds holding LSTA

DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
FCMT
Founders Capital Management (Texas) Houston, Texas $231M AUM 61.68% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

International Assets Investment Management's LSTA Position: Q2 2026 in Review

International Assets Investment Management held its Lisata Therapeutics (LSTA) position steady in Q2 2026 at 5,000 shares worth $16.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1673.

International Assets Investment Management first reported a position in LSTA in Q4 2025 and has held it in 3 quarters since. The position peaked at $25.1K in Q1 2026. 5 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.

  • International Assets Investment Management held 5,000 shares of Lisata Therapeutics worth $16.8K as of Q2 2026.
  • International Assets Investment Management left its Lisata Therapeutics share count unchanged in Q2 2026.
  • Lisata Therapeutics made up ﹤0.01% of International Assets Investment Management's portfolio in Q2 2026, its #1673 holding.
  • International Assets Investment Management first reported a position in Lisata Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • International Assets Investment Management's Lisata Therapeutics position peaked at $25.1K in Q1 2026.
  • 5 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.

Based on International Assets Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.